Vela Pharmaceuticals Appoints Praveen Tyle, Ph.D., Senior Vice-President of Research & Development and Chief Scientific Officer at Bausch & Lomb, to Scientific Advisory Board.EWING, N.J. -- Vela vela plural of velum. Pharmaceuticals (Vela), a privately-held company specializing in the "re-discovery and development" of nervous system medicines, announced today the election of Praveen Tyle, Ph.D. to the company's Scientific Advisory Board (SAB). Dr. Tyle is an expert in pharmaceutical development and drug delivery with over 20 years of pharmaceutical industry management experience. He was recently named Senior Vice President of R&D and Chief Scientific Officer at Bausch & Lomb, Inc., the global eye health company, where he directs global drug and device researchers and developers. Prior to joining Bausch & Lomb, Dr. Tyle held management roles with such companies as Pharmacia (now Pfizer), Agouron (now Pfizer), Sandoz Pharmaceuticals (now Novartis), and American Cyanamid (now Wyeth). He has co-edited seven books about drug development and has authored over one hundred scientific papers and presentations. He also holds several patents. Dr. Tyle received his Ph.D. in Drug Delivery and Physical Pharmacy from The Ohio State University Ohio State University, main campus at Columbus; land-grant and state supported; coeducational; chartered 1870, opened 1873 as Ohio Agricultural and Mechanical College, renamed 1878. There are also campuses at Lima, Mansfield, Marion, and Newark. . "Dr. Tyle brings to Vela a wealth of experience in both drug delivery and drug discovery," said Kevin L. Keim, Ph.D., M.Sc., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Vela. "The capacity to think creatively about new formulations and delivery methods is important to Vela's 're-discovery and development' strategy for adding value to pharmaceutical assets." Vela Scientific Advisory Board Vela's Scientific Advisory Board is composed of world-class experts in drug development, clinical trials, patient care, and scientific discovery. Members advise Vela on the in-licensing, re-discovery, and development of CNS-related assets. Vela's current Scientific Advisory Board includes the following: George A. Clay, Ph.D., former Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. , Kyowa Pharmaceuticals; Martin B. Keller, M.D. (Chairman), Brown University Department of Psychiatry; Donald F. Klein, M.D., Columbia University College of Physicians and Surgeons The Columbia University College of Physicians and Surgeons, abbreviated P&S, is a graduate school of Columbia University located on the health sciences campus in the Washington Heights neighborhood of Manhattan. ; Ranga Krishnan, M.D., Duke University Medical Center; Harley R. Liker, M.D., M.B.A., David Geffen School of Medicine at UCLA UCLA School of Medicine or David Geffen School of Medicine at UCLA is an accredited allopathic medical school located in Los Angeles, California, United States. The school was named in honor of media mogul David Geffen who donated $200 million in unrestricted funds to the ; and Stuart A. Montgomery, M.D., Imperial College School of Medicine The Imperial College School of Medicine is the medical school of Imperial College London in England. The Faculty of Medicine was established in 1997, bringing together all the major West London medical schools into one world-class institution (see infra). . About Vela Pharmaceuticals Based in New Jersey, Vela Pharmaceuticals Inc. (www.velapharm.com) is a privately-held company specializing in the "re-discovery and development" of medicines related to the nervous system. Vela's current portfolio includes an asset in Phase 2 for the treatment of depression, an asset in Phase 2 for the treatment of irritable bowel syndrome irritable bowel syndrome (IBS), condition characterized by frequently alternating constipation and diarrhea in the absence of any disease process. It is usually accompanied by abdominal pain, especially in the lower left quadrant, bloating, and flatulence. , and an asset in Phase 1b for the treatment of menopausal hot flashes. Investors include JP Morgan Partners, New Enterprise Associates, and Venrock Associates. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion